Table 3 Comparison of trials on LMWH versus VKA for treatment of VTE in cancer patients
Trial Name | CANTHANOX | CLOT | MAIN-LITE | ONCENOX | CATCH |
|---|---|---|---|---|---|
Year of Publication [Ref] | 2002 [43] | 2003 [44] | 2006 [45] | 2006 [46] | 2015 [47] |
Design | Open-label | Open-label | Open-label | Open-label | Open-label |
Number of Patients | 146 | 676 | 200 | 122 | 900 |
Treatment Protocol | Enoxaparin 1.5Â mg/kg daily | Dalteparin 200Â IU/kg once daily for the first month then 150Â IU/kg for 5Â months | Tinzaparin 175Â IU/kg once daily | Enoxaparin 1Â mg/kg every 12Â h for 5Â days then enoxaparin 1Â mg/kg or 1.5Â mg/kg daily | Tinzaparin 175Â IU/kg once daily |
Duration of Therapy (months) | 3 | 6 | 3 | 6 | 6 |
Primary Efficacy Outcome LMWH vs VKA (%) | Combination of major bleeding or recurrent VTE: 10.5 vs 21.1 | Recurrent symptomatic VTE: 9a vs 17 | Recurrent symptomatic VTE: 7 vs 10 | Recurrent symptomatic VTE: enoxaparin 1Â mg vs. 1.5Â mg vs VKA 6.8 vs 6.3 vs 10.0 | Composite of recurrent symptomatic VTE, fatal PE, or incidental VTE: 7.2 vs 10.5 |
Safety Bleeding Outcomes LMWH vs VKA (%) | Major bleeding: 7 vs 16; Fatal bleeding: 0 vs 8a | Major bleeding: 6 vs 4; Any bleeding 14 vs 19 | Major bleeding: 7 vs 7; Any bleeding: 27 vs 24 | Major bleeding: enoxaparin 1Â mg vs. 1.5Â mg vs VKA : 6.5 vs 11.1 vs 2.9 | Major bleeding: 2.7 vs 2.4 CRNM bleeding: 10.9a vs 15.3 |